Organon & Co. (OGN) to Release Quarterly Earnings on Thursday

Organon & Co. (NYSE:OGNGet Free Report) is scheduled to be announcing its earnings results before the market opens on Thursday, February 15th. Analysts expect the company to announce earnings of $0.71 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Organon & Co. Price Performance

Shares of OGN stock opened at $16.25 on Thursday. The company’s fifty day simple moving average is $14.60 and its two-hundred day simple moving average is $16.66. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $29.84. The stock has a market capitalization of $4.15 billion, a price-to-earnings ratio of 7.10, a PEG ratio of 0.47 and a beta of 0.79.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Bank of America lowered their price objective on shares of Organon & Co. from $23.00 to $19.00 in a research note on Thursday, October 12th. The Goldman Sachs Group downgraded shares of Organon & Co. from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $33.00 to $16.00 in a research report on Friday, November 3rd. Piper Sandler dropped their price objective on shares of Organon & Co. from $32.00 to $22.00 and set an “overweight” rating for the company in a research note on Wednesday, November 22nd. Finally, Morgan Stanley dropped their price target on shares of Organon & Co. from $27.00 to $22.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 11th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Organon & Co. has an average rating of “Moderate Buy” and a consensus target price of $23.33.

Get Our Latest Stock Report on OGN

Institutional Trading of Organon & Co.

A number of institutional investors have recently added to or reduced their stakes in OGN. Fairfield Bush & CO. grew its position in Organon & Co. by 3.0% in the 1st quarter. Fairfield Bush & CO. now owns 16,302 shares of the company’s stock worth $569,000 after purchasing an additional 481 shares during the last quarter. Natixis Advisors L.P. lifted its position in shares of Organon & Co. by 52.5% in the 1st quarter. Natixis Advisors L.P. now owns 50,428 shares of the company’s stock valued at $1,761,000 after acquiring an additional 17,370 shares in the last quarter. MetLife Investment Management LLC lifted its position in Organon & Co. by 23.2% in the 1st quarter. MetLife Investment Management LLC now owns 68,987 shares of the company’s stock worth $2,410,000 after buying an additional 12,969 shares in the last quarter. Panagora Asset Management Inc. lifted its position in Organon & Co. by 95.6% in the 1st quarter. Panagora Asset Management Inc. now owns 39,595 shares of the company’s stock worth $1,383,000 after buying an additional 19,352 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Organon & Co. by 6.6% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,926 shares of the company’s stock valued at $1,185,000 after purchasing an additional 2,101 shares in the last quarter. 77.08% of the stock is owned by hedge funds and other institutional investors.

About Organon & Co.

(Get Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Recommended Stories

Earnings History for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.